BGM Group (NASDAQ:BGM) Given Sell (D) Rating at Weiss Ratings

Key Points

• BGM Group's stock has been given a "sell (d)" rating by Weiss Ratings, indicating negative sentiment towards the stock's performance.
• Wall Street Zen recently downgraded BGM Group's rating from "buy" to "hold", contributing to the overall consensus rating of "Sell" among analysts.
• An institutional investor, Geode Capital Management LLC, acquired 38,913 shares of BGM Group stock, valued at approximately $412,000, during the second quarter.

BGM Group (NASDAQ:BGM - Get Free Report)'s stock had its "sell (d)" rating reissued by stock analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen lowered BGM Group from a "buy" rating to a "hold" rating in a research note on Sunday, July 6th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Sell".

BGM Group Price Performance

BGM stock traded up $0.19 during trading on Wednesday, reaching $9.88. The company had a trading volume of 26,541 shares, compared to its average volume of 48,378. The business has a 50 day moving average of $8.48 and a 200 day moving average of $10.49. BGM Group has a 52 week low of $6.22 and a 52 week high of $17.17.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BGM Group stock. Geode Capital Management LLC acquired a new position in shares of BGM Group Ltd. (NASDAQ:BGM - Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 38,913 shares of the company's stock, valued at approximately $412,000.

BGM Group Company Profile

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.